NIAID-VRC- Rapid Manufacturing Response

NIAID-VRC-快速制造响应

• 批准号: 10722383
• 负责人: DAVID LINDSAY
• 金额: $ 982.24万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-16 至 2027-09-15
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10722383
• 关键词: 2019-nCoV; Antibodies; Clinic; Clinical; Clinical Trials; Development; HIV; Investigation; Mission; National Institute of Allergy and Infectious Disease; Phase; Process; Production; Research; Safety; Testing; Time; Vaccine Research; Vaccines; clinical candidate; first-in-human; flu; new technology; public health emergency; response

The Vaccine Research Center (VRC) mission and scope includes rapidly moving clinical candidates from the research bench through development and GMP manufacturing to the clinic. The VRC is exploring a wide range of initiatives, including but not limited to new technologies which would decrease the time between candidate discovery and first-in-human clinical trials. These initiatives will allow VRC and NIAID to quickly assess clinical stage products for safety and efficacy and to expedite the production and supply of investigational products to the field during public health emergencies.

疫苗研究中心（VRC）的任务和范围包括从研究工作台迅速移动临床候选者，从开发和GMP制造到诊所。 VRC正在探索广泛的举措，包括但不限于新技术，这些技术将减少候选人发现与首次人类临床试验之间的时间。这些举措将使VRC和NIAID能够快速评估临床阶段产品的安全性和功效，并加快在公共卫生紧急情况下向现场的研究产品的生产和供应。